Sculptor Capital LP Has $24.49 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Sculptor Capital LP grew its stake in Boston Scientific Co. (NYSE:BSX) by 84.9% during the second quarter, HoldingsChannel.com reports. The firm owned 318,000 shares of the medical equipment provider’s stock after buying an additional 146,000 shares during the period. Sculptor Capital LP’s holdings in Boston Scientific were worth $24,489,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Precision Wealth Strategies LLC bought a new position in Boston Scientific during the 4th quarter worth about $956,000. Aveo Capital Partners LLC lifted its stake in Boston Scientific by 1.3% in the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock valued at $742,000 after purchasing an additional 171 shares during the last quarter. D.A. Davidson & CO. lifted its stake in Boston Scientific by 6.0% in the 4th quarter. D.A. Davidson & CO. now owns 9,380 shares of the medical equipment provider’s stock valued at $542,000 after purchasing an additional 529 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in Boston Scientific by 19.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 25,379 shares of the medical equipment provider’s stock worth $1,467,000 after acquiring an additional 4,127 shares during the last quarter. Finally, TD Asset Management Inc lifted its position in Boston Scientific by 10.7% during the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after acquiring an additional 155,565 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $77.30, for a total value of $539,785.90. Following the sale, the executive vice president now owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 20,949 shares of company stock valued at $1,627,877 in the last quarter. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BSX shares. Barclays lifted their price target on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Boston Scientific in a research note on Thursday, July 25th. Canaccord Genuity Group lifted their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $86.65.

Boston Scientific Stock Down 0.5 %

Boston Scientific stock opened at $83.08 on Friday. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $84.89. The firm has a 50 day moving average price of $79.22 and a 200-day moving average price of $75.07. The company has a market capitalization of $121.89 billion, a P/E ratio of 69.82, a P/E/G ratio of 2.78 and a beta of 0.79. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.53 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.4 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.